Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 17/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521478 | 1.00 | ALPL (0.55) | ALPLLMNASMN1; SMN2SLC22A12ALOX12 | |
| SCHEMBL4510840 | 0.86 | HSD11B1 (0.48) | — | |
| SCHEMBL4515527 | 0.85 | HTR6 (0.39) | ALPLLMNASMN1; SMN2 | |
| SCHEMBL4510831 | 0.85 | PKM (0.39) | — | |
| SCHEMBL4965833 | 0.85 | PKM (0.39) | — | |
| SCHEMBL4514033 | 0.84 | HSD11B1 (0.39) | ALPLLMNASLC22A12 | |
| SCHEMBL4518286 | 0.83 | ALPL (0.51) | ALPLLMNA | |
| SCHEMBL4514462 | 0.82 | ALDH1A1 (0.48) | SMN1; SMN2 | |
| SCHEMBL4518619 | 0.82 | ALPL (0.59) | ALPLLMNASMN1; SMN2SLC22A12 | |
| SCHEMBL4519515 | 0.82 | MTNR1A (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888518-A1 | NOVEL 8-SULFONYL-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | AstraZeneca AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006126938-A1 | NOVEL 8-SULFONYL-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |